崔孔蛟 1周雨 1王传琨 1雷良 1武慧明 1刘志宏2
作者信息
- 1. 民航上海医院-瑞金医院古北分院,上海200336
- 2. 上海交通大学医学院附属瑞金医院,上海200025
- 折叠
摘要
Abstract
Objective To study the safety and adverse effects of 5 mg zoledronic acid in the treatment of osteoporosis.Methods From May 2016 to Feb 2017,17 patients with osteoporosis,aged from 57 to 83 years,with an average age of 70.12±7.53 years,were enrolled in this study.4 males and 13 females,of which 4 cases had oral administration of alendronate sodium in the treatment ofosteoporosis.All patients were treated with intravenous zoledronic acid 5mg,calcitriol and calcium tablets 600mg orally,patients before intravenous zoledronic acid and 24 hours after intravenous infusion of liver and kidney function,blood,CRP,ESR,etc.Biochemical index and clinical adverse reaction were analyzed statistically.Results The percentage ofbody temperature,calcium,phosphorus,neutrophil percentage and percentage of lymphocytes in the intravenous infusion of 5 mg zoledronic acid before and after intravenous infusion was statistically significant (P＜0.001,respectively),the intravenous infusion of 5 mg zoledronic acid 24 hours after the body temperature and neutrophil percentage increased intravenous infusion,calcium,phosphorus and lymphocyte percentage slightly more intravenous drop slightly;CRP,creatinine were statistically significant,in which CRP increased intravenously before the intravenous infusion of creatinine low.There was no statistically significant difference in the total number of white blood cells before and after intravenous infusion.Clinical manifestations of fever in 11 cases,accounting for 64.71％,of which the maximum temperature of 39.3℃;palpitation with anorexia in 1 case,accounting for 5.89％;fatigue,myalgia and other flu symptoms in 2 cases,accounting for 11.76％;2 ～ 3 days follow,no recurrence of clinical symptoms.Conclusion 5 mg zoledronic acid intravenous treatment of osteoporosis without obvious adverse effects on the body,and easy to use,suitable for outreach and can be recommended to promote the use and improve compliance and treatment of osteoporosis treatment.关键词
唑来膦酸/骨质疏松症,骨密度/不良反应/安全性Key words
Zoledronic acid/Osteoporosis, Bone mineral density/Adverse reaction/Safety分类
医药卫生
